Results of Operations and Financial Condition. On August 6, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Results of Operations and Financial Condition. On May 7, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Director — Eric Dobmeier: The reclassification was done to achieve a more equal balance of membership among the three classes of directors on the Board.

Results of Operations and Financial Condition. On February 26, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Entry into Material Definitive Agreement. On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types (the “Collaboration Target”). Licenses and Exclusivity . Under the Collaboration A…

Results of Operations and Financial Condition. On November 6, 2025, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Chief Strategy Officer — Byron Robinson, Ph.D.: Byron Robinson ceased to serve as Chief Strategy Officer and departed the company.

Results of Operations and Financial Condition. On August 7, 2025, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Results of Operations and Financial Condition. On May 8, 2025, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Results of Operations and Financial Condition. On February 27, 2025, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Other Events. On December 4, 2024, Janux Therapeutics, Inc. (“we” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (…

Other Events. On December 2, 2024, the Company announced updated interim clinical data for its JANX007 clinical program. Updated interim, clinical data for PSMA-TRACTr JANX007 in mCRPC as of November 15, 2024 JANX007 is in a Phase 1a clinical trial in patients with advanced or metastatic prostate cancer (“mCRPC”). The patients enrolled in the trial were heavily pre-treated with a median of four prior lines of therapy. As of the November 15, 2024 data cutoff, 16 pre-PLUVICTO® patients have bee…

Results of Operations and Financial Condition. On November 6, 2024, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Results of Operations and Financial Condition. On August 7, 2024, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Chair of the Board of Directors — Jay Lichter, Ph.D.: Dr. Jay Lichter resigned from the Board of Directors and his resignation was not a result of any disagreement with the Company.

Results of Operations and Financial Condition. On May 7, 2024, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Results of Operations and Financial Condition. On March 8, 2024, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…

Other Events. On February 28, 2024, Janux Therapeutics, Inc. (“we” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Cowen and Company, LLC, Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 4,440,851…

Other Events. On February 28, 2024, Janux Therapeutics, Inc. (the “Company”) delivered written notice to BofA Securities, Inc. (“BofA”), that it was suspending the prospectus supplement, dated May 9, 2023, related to the Company’s common stock, $0.001 par value per share, issuable pursuant to the terms of the ATM Equity Offering SM Sales Agreement, dated May 9, 2023, by and between the Company and BofA (the “Sales Agreement”). The Company will not make any sales of common stock pursuant to th…

Results of Operations and Financial Condition. On November 7, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Results of Operations and Financial Condition. On August 8, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Entry into a Material Definitive Agreement. On July 17, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Offering”) by the Company of (i) 4,153,717 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share…

Results of Operations and Financial Condition. As of the date hereof, based on currently available information, Janux Therapeutics, Inc (“we,” “us,” “our,” and the “Company”) expects its cash, cash equivalents, restricted cash and short-term investments as of June 30, 2023 to be approximately $304.1 million. Inclusive in this amount is $0.8 million of restricted cash that is not available for current use. The preliminary results set forth above are based on management’s initial review of our…

Chief Medical Officer — Wayne Godfrey, M.D.: Dr. Godfrey resigned for personal reasons.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed by Janux Therapeutics, Inc. (the “Company”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on March 31, 2023 and its Proxy Statement filed with the Commission on April 28, 2023, an independent director, Peter Thompson, M.D., did not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “An…